Dr. John Leonard Describes Treatments Available to Patients with Indolent B-cell Non-Hodgkin Lymphoma

In this video from Onc Live, Lymphoma Program Director, Dr. John P. Leonard, describes treatment options available to patients with indolent B-cell non-Hodgkin lymphoma.

Current treatment options for NHL include single-agent rituximab, R-CHOP, and bendamustine plus rituximab. Although early data shows potential for lenalidomide alone or in combination with rituximab.

The variety of options available for patients with indolent B-cell non-Hodgkin lymphoma is due to extensive clinical trial testing. If you are interested in learning more information about the clinical trials available at Weill Cornell Medicine you can visit the Joint Clinical Trials website.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s